A combined vaccine against anthrax in animals |
|
IPC classes for russian patent A combined vaccine against anthrax in animals (RU 2220742):
    
The method of processing of crop products before putting it into storage / 2220536
The invention relates to technologies for primary processing of crop products, food and fodder before putting it into storage
 The enzyme preparation having endogenously activity decomposition of rhamnogalacturonan-ii (rg-ii), the method of its production, the strains of the fungus penicillium daleae and penicillium simplicissimum with endogenously activity decomposition of rhamnogalacturonan-ii(rg-ii) (options), the method of selection of strains with endogenously activity decomposition of rhamnogalacturonan-ii(rg-ii) and the use of enzyme preparation / 2220203
The invention relates to biotechnology and concerns enzyme preparation decomposition of rhamnogalacturonan II (RG-II) with an activity of endo-
 -L-rhamnopyranose -(1-->3')-D - apiformis-hydrolases and endo- -L-fucopyranoside -(1-->4)-L-rhamnopyranose-hydrolases derived from a strain of Penicillium daleae CNCN 1-1578 (LAV 2) and strain Penicillium simplicis-simum CNCN 1-1577 (IPVI)
 The strain of the fungus penicillium estinogenum a. komatsu et s. abe ex g. sm. producing endonuclease pestand how you can get / 2220198
The invention relates to biotechnology, in particular the production of enzymes and can be used to obtain highly active endonuclease Rest[EU 3.1.4.21] - the single-stranded nucleic-5-oligonucleotide hydrolases, which can be used in molecular biology in the study of the primary structure of deoxyribonucleic acid and ribosomal structure, transport, and viral RNA in genetic engineering to obtain recombinantly molecules and obtain 5'-RIBO - 5'-deoxyribonucleotides of ribonucleic acid and deoxyribonucleic acid
 The method of obtaining food biosorbent / 2219997
The invention relates to the microbiological industry, and specifically to methods for biosorbent by microbiological synthesis, which can be used as activator beer fermentation
Method for the production of sterilized canned / 2219774
The invention relates to the technology of canning
The method of processing of crop products before putting it into storage / 2219731
The invention relates to technologies for primary processing of crop products, food and fodder before putting it into storage
The method of processing of crop products before putting it into storage / 2219730
The invention relates to technologies for primary processing of crop products, food and fodder before putting it into storage
The method of processing of crop products before putting it into storage / 2219729
The invention relates to technologies for primary processing of crop products, food and fodder before putting it into storage
The method of processing of crop products before putting it into storage / 2219727
The invention relates to technologies for primary processing of crop products, food and fodder before putting it into storage
 Integrated prevention of anthrax / 2216349
The invention relates to medicine, infectious diseases and can be used for integrated prevention of anthrax
 Globulin protivoseborainey horse dry / 2214836
The invention relates to the field of biotechnology and immunology, and can be used to stabilize the physicochemical and biologic properties globulin protivovirusnogo
 A method for the treatment of generalized forms of anthrax infection / 2214834
The invention relates to medicine, infectious diseases and can be used for the treatment of generalized forms of anthrax infection
 The way to obtain serum for the identification of the causative agent of anthrax / 2191603
The invention relates to medical Microbiology and the receipt of anthrax serum, allowing to distinguish Bacillus anthracis from closely related microorganisms
The associated vaccine to prevent anthrax and nitrobacteria animals / 2191599
The invention relates to the field of veterinary medicine and biotechnology
 The method of obtaining dry combination anthrax vaccine / 2181294
The invention relates to medical immunobiological preparations, in particular to the anthrax vaccine, and can be used in medicine and veterinary medicine for the prevention of anthrax
Strain of bacillus anthracis km90 is the basis for genetic engineering of producers anthrax antigens / 2180917
The invention relates to biotechnology and can be used in Microbiology, immunology and veterinary medicine
Strain of bacillus anthracis km92-producer of anthrax antigens / 2180916
The invention relates to biotechnology and can be used in Microbiology, genetics, biochemistry
 Biological drug for prevention and treatment of gastrointestinal diseases in young animals / 2180851
The invention relates to veterinary medicine, namely to veterinary Microbiology and therapy
 A method for concentrating spore cultures in the production of the anthrax vaccine / 2151798
The invention relates to the production technology of medical immunobiological preparations, in particular, to a method of concentrating spore cultures in the production of the anthrax vaccine, ensuring the stability of their biological properties with preservation of potency, and can be used in the practice of production of the anthrax vaccine
 Method for production of immune serum to virulent strain bacillus anthracis antigen / 2252031
Claimed method includes administering before contamination to the animal subsequently in right pope then after 14 days in left pope 0.2 ml of non-complete Freund's adjuvant with equal volume of physiological salt solution. Subsequent administering after 14 days in right pope up to 10 LD50 of Bacillus anthracis 81/1 spore dredge doesn't cause animal death for long period (monitoring time is 35 days).
|
The invention relates to veterinary biology and immunology, in particular to the production and application of biological preparations for vaccination of animals. The proposed vaccine includes protective antigen vaccine strain 55 Vniivvim concentration (17,5 2,5) immunizing doses and live spores vaccine strain STI-1 concentration (2,50,3) 107in 1 ml of physiological solution. The proposed vaccine is harmless, provides for the establishment of a busy antitoxic and antibacterial immunity against anthrax. The invention can be used for specific prophylaxis of anthrax. 6 table.
The present invention relates to the field of veterinary biotechnology and immunology, in particular to the production of vaccines for specific prophylaxis of anthrax in animals.
Anthrax is a disease occurring in the form of skin, intestinal and pulmonary forms, occurring in the form of single and group of diseases. To anthrax susceptible to many species of domestic and wild animals. Home sick animals large and small cattle, pigs, camels, buffaloes, economical and social damage, therefore, the development of a highly effective vaccine that provides intense and long-lasting immunity against the infection is current.
It is now widely known "STI live Vaccine against anthrax in animals". It can be produced in two forms.
- Dry vaccine STI is a dried under vacuum homogeneous porous tablet consisting of living spores backupsonline slabovrajennoe culture of the anthrax strain STI-1 and filler.
- Liquid STI vaccine is a suspension of live spores backupsonline slabovrajennoe culture of the anthrax strain STI 30-nom neutral solution of glycerol (1).
Known vaccine against anthrax and emphysematous carbuncle living associated, including suspension of spores of anthrax avirulent vaccine strain 55 Vniivvim in the initial concentration (2.0 to 2.5)109the dispute in 1 cm3and (2,0-2,1)109viable cells of strain emphysematous carbuncle and saline solution in the following ratio, wt.%: The spores of the anthrax strain 55 Vniivvim with the initial concentration (2.0 to 2.5)109the dispute is p>9- 95,0 - 97,0 saline - Else Vaccine is injected subcutaneously in the region of the middle third of the neck cattle aged from 3 to 6 months. 1.0 to 1.1 cm3(2).
Known combined anthrax vaccine for humans, including live spores of strain STI-1 and the protective antigen (PA), obtained under certain conditions of cultivation of this vaccine strain. The time of formation of a busy immunity in humans against anthrax infection is 7-10 days after a single immunization.
Comparative trials of this vaccine in laboratory and farm animals has shown its significant advantages over currently used in veterinary practice protivovirusnymi vaccines on the basis of individual strains 55 Vniivvim or STI. Degree productivity was low (3).
The objective of our research was to develop a combined vaccine against anthrax based on the binary combination of live spores vaccine strain STI-1 and protective antigen, obtained from microbial culture vaccine strain 55 Vniivvim for creating in the body vaccinated animals intense and long-lasting immunity, harmless and is zindoga strain STI-1 concentration (2,50,3)107protective antigen-based microbial culture vaccine strain 55 Vniivvim activity (17,52,5) immunizing doses of 1 ml, with the following ratio of components: protective antigen vaccine strain 55 Vniivvim concentration (17,52,5) immunizing doses and live spores vaccine strain STI-1 concentration (2,50,3)107spores in 1 ml of physiological solution.
The vaccine is prepared as follows.
Technological scheme of production includes the following basic stages.
- Preparation of the working culture production strain STI-1 in the usual way, subject content 1 cm3culture medium is not less than 2.5 billion spores., optimally (2,50,3)107.
- Preparation of nutrient media and additional solutions.
- Growing native spore culture.
The cultivation is carried out in the cultivators. Sowing culture of one ampoule before sowing is activated by heating in ultramontane.
Cultivation was carried out under continuous mechanical stirring, aeration with the Finance and the absence of extraneous microflora.
Then when reaching into the culture 70-75% stop stirring, the air supply. Next, the native culture is warmed up to 36-37oC and maintained with periodic stirring for 3-5 hours, then cooled culture to 15-20oC.
Selected native culture must meet the following requirements: - not contain extraneous microflora; - to contain not less than 90% of normal colored spores; - to have total concentration of the dispute is not less than 1.5 billion in 1 cm3cultural environment; - to have a value of pH of 8.2-8,9 pH unit.
Getting spore concentrate.
Getting spore concentrate is carried out in the usual way, under the following conditions:- not contain extraneous microflora; - the total concentration of spores in the suspension should be at least 12 billion spores per 1 cm3; - to contain not less than 90% of the spores and to have a pH of 7.0 to 8.5 pH units. If necessary, the concentrate is diluted SW. water and re control. Then separately allocate a protective antigen from the culture medium vaccine strain 55 Vniivvim. Then hold the components are mixed vaccines: spores from strain STI-1 concentration (2,5 0,3)107dispute and protectivegear solution.
The vaccine is administered prophylactically once for preventive vaccinations of all kinds of farm animals. Initially vaccinated animals (young) subjected to immunization twice.
The vaccine percutaneously applied in the following doses:- sheep and goats - in the region of the middle third of the neck or inner thigh in a volume of 0.5 ml of reconstituted vaccine; - cattle, deer and donkeys in the area of the middle third of the neck in a volume of 1.0 ml of the reconstituted vaccine; - pigs - in area of the inner thigh or behind the ear in a volume of 1.0 ml of the reconstituted vaccine; - fur animals - in area of the inner thigh or podgotovke mirror in a volume of 1.0 ml of the reconstituted vaccine. Specific examples for testing the proposed vaccine are shown in tables 1-6. In addition, the application should include four tables 3-6 comparative characterization of immunogenic properties of the anthrax vaccine in Guinea pigs, tension immunity in Guinea pigs after immunization with different anthrax vaccines and immunity stress level of antibodies in sheep and cattle immunized against anthrax. The proposed combined creating antimicrobial immunity, and the presence of protective antigen derived from microbial cultures vaccine strain 55 Vniivvim, provides for the creation of antitoxic immunity. The vaccine is harmless, does not cost much and after a single dose in the body of the animal enables the creation of long and intense immunity (antimicrobial and antitoxic) against anthrax. The proposed vaccine has been tested with positive results from 1998 to 2001 in Azerbaijan 900 thousand heads of large and 5 million head of small cattle. In addition, the vaccine has been tested since 1998, but in 2000 per 100,000 cattle and 3 million head of small cattle in the livestock farms in Turkmenistan. The proposed vaccine will be used in the livestock farms in the country to combat one of the most dangerous diseases - anthrax animals, as well as provide epidemiological welfare of the population. Sources of information 1. "STI live vaccine against anthrax in animals". THE GOST 15991 - 86 the state Committee for standards, Moscow. 2. RF patent 2112544, class a 61 K 39/116, 1998. 3. The Ministry of health 132 from 16.04.92. "On the permit application in health care practice new medical immunologists is the Qing against anthrax in animals on the basis of live spores vaccine strain STI-1, characterized in that it further comprises a protective antigen vaccine strain 55 Vniivvim, the components included in the vaccine, take the following ratios: live debate vaccine strain STI-1 concentration (2,5 0,3) 107dispute and protective antigen vaccine strain 55 Vniivvim concentration (17,52,5)ID50(immunizing doses for white mice) in 1 ml of physiological solution.
|